Clinical Trials Logo

Central Line Fungal Infections clinical trials

View clinical trials related to Central Line Fungal Infections.

Filter by:
  • None
  • Page 1

NCT ID: NCT00936910 Completed - Clinical trials for Central Line Fungal Infections

Antifungal Locks to Treat Fungal-related Central Line Infections

Start date: September 2006
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate the usefulness of antifungal lock therapy with liposomal amphotericin B (Ambisome), in combination with systemic antifungal(s), in patients with catheter-related blood stream infections with fungal organisms, whose catheter has not been removed because of the continuing critical need for central line access. The primary group of potential patients will be those with intestinal insufficiency, including post-op small bowel transplant recipients. The recommendation of the Infectious Disease Society of America (IDSA) is to remove all catheters with fungal infections and treat systemically for 14 days after the last positive culture. However, in certain intestinal failure patients, removal of an infected line might significantly reduce or eliminate intravenous (IV) access and create a life threatening situation. Thus, the investigators' aim is to determine the usefulness of antifungal lock therapy in intestinal failure patients whose catheter has not been removed. The investigators' hope is to salvage central line catheters rather than to remove them.